Hostname: page-component-669899f699-qzcqf Total loading time: 0 Render date: 2025-04-24T21:07:46.007Z Has data issue: false hasContentIssue false
  • English
  • Français

Heart failure biomarker levels correlate with invasive haemodynamics in pulmonary valve replacement

Published online by Cambridge University Press:  27 November 2019

Phillip M. Zegelbone Open the ORCID record for Phillip M. Zegelbone [Opens in a new window] ,
Richard E. Ringel ,
John D. Coulson ,
Melanie K. Nies ,
Meagan E. Stabler ,
Jeremiah R. Brown  and
Allen D. Everett
Phillip M. Zegelbone
Affiliation:
Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA
Richard E. Ringel
Affiliation:
Division of Pediatric Cardiology, Johns Hopkins Children’s Center, Baltimore, MD, USA
John D. Coulson
Affiliation:
Division of Pediatric Cardiology, Johns Hopkins Children’s Center, Baltimore, MD, USA
Melanie K. Nies
Affiliation:
Division of Pediatric Cardiology, Johns Hopkins Children’s Center, Baltimore, MD, USA
Meagan E. Stabler
Affiliation:
Department of Epidemiology, Geisel School of Medicine, Lebanon, NH, USA
Jeremiah R. Brown
Affiliation:
Department for Biomedical Data Science, Geisel School of Medicine, Lebanon, NH, USA
Allen D. Everett*
Affiliation:
Division of Pediatric Cardiology, Johns Hopkins Children’s Center, Baltimore, MD, USA
*
Author for correspondence: A. Everett, MD, Pediatric Cardiology, Johns Hopkins Children’s Center, 1800 Orleans Street, Baltimore, MD 21231, USA. Tel: +1 410 955 5987; Fax: +1 410 955 0897. E-mail: aeveret3@jhmi.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Although widely used in cardiology, relation of heart failure biomarkers to cardiac haemodynamics in patients with CHD (and in particular with pulmonary insufficiency undergoing pulmonary valve replacement) remains unclear. We hypothesised that the cardiac function biomarkers N-terminal pro-brain natriuretic peptide (NT-proBNP), soluble suppressor of tumorigenicity 2, and galectin-3 would have significant associations to right ventricular haemodynamic derangements.

Methods:

Consecutive patients ( n = 16) undergoing cardiac catheterisation for transcatheter pulmonary valve replacement were studied. NT-proBNP, soluble suppressor of tumorigenicity 2, and galectin-3 levels were measured using a multiplex enzyme-linked immunosorbent assay from a pre-intervention blood sample obtained after sheath placement. Spearman correlation was used to identify significant correlations (p ≤ 0.05) of biomarkers with baseline cardiac haemodynamics. Cardiac MRI data (indexed right ventricular and left ventricular end-diastolic volumes and ejection fraction) prior to device placement were also compared to biomarker levels.

Results:

NT-proBNP and soluble suppressor of tumorigenicity 2 were significantly correlated (p < 0.01) with baseline mean right atrial pressure and right ventricular end-diastolic pressure. Only NT-proBNP was significantly correlated with age. Galectin-3 did not have significant associations in this cohort. Cardiac MRI measures of right ventricular function and volume were not correlated to biomarker levels or right heart haemodynamics.

Conclusions:

NT-proBNP and soluble suppressor of tumorigenicity 2, biomarkers of myocardial strain, significantly correlated to invasive pressure haemodynamics in transcatheter pulmonary valve replacement patients. Serial determination of soluble suppressor of tumorigenicity 2, as it was not associated with age, may be superior to serial measurement of NT-proBNP as an indicator for timing of pulmonary valve replacement.

Keywords

Biomarkerpulmonary valvetetralogy of Fallot
Type
Original Article
Information
Cardiology in the Young , Volume 30 , Issue 1 , January 2020 , pp. 50 - 54
Copyright
© Cambridge University Press 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Ooi, A, Moorjani, N, Baliulis, G, et al. Medium term outcome for infant repair in tetralogy of Fallot: indicators for timing of surgery. Eur J Cardiothorac Surg 2006; 30: 917–922.CrossRefGoogle ScholarPubMed
Lee, C, Lee, CN, Kim, SC, et al. Outcome after one-stage repair of tetralogy of Fallot. J Cardiovasc Surg (Torino) 2006; 47: 65–70.Google ScholarPubMed
Murphy, JG, Gersh, BJ, Mair, DD, et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med 1993; 329: 593–599.CrossRefGoogle ScholarPubMed
Nollert, G, Fischlein, T, Bouterwek, S, et al. Long-term survival in patients with tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. J Am Coll Cardiol 1997; 30: 1374–1383.CrossRefGoogle ScholarPubMed
Geva, T, Sandweiss, BM, Gauvreau, K, et al. Factors associated with impaired clinical status in long-term survivors of tetralogy of Fallot repair evaluated by magnetic resonance imaging. J Am Coll Cardiol 2004; 43: 1068–1074.CrossRefGoogle ScholarPubMed
Silka, MJ, Hardy, BG, Menashe, VD, et al. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 1998; 32: 245–251.CrossRefGoogle ScholarPubMed
Khairy, P, Aboulhosn, J, Gurvitz, MZ, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. Circulation 2010; 122: 868–875.CrossRefGoogle ScholarPubMed
Meijboom, FJ, Roos-Hesselink, JW, McGhie, JS, et al. Consequences of a selective approach toward pulmonary valve replacement in adult patients with tetralogy of Fallot and pulmonary regurgitation. J Thorac Cardiovasc Surg 2008; 135: 50–55.CrossRefGoogle ScholarPubMed
Therrien, J, Provost, Y, Merchant, N, et al. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol 2005; 95: 778–782.CrossRefGoogle ScholarPubMed
Buechel, ER, Dave, HH, Kellenberger, CJ, et al. Remodeling of right ventricle after early pulmonary valve replacement in children with repaired tetralogy of Fallot: assessment by cardiovascular magnetic resonance. Eur Heart J 2005; 26: 2721–2727.CrossRefGoogle ScholarPubMed
Ammash, NM, Dearani, JA, Burkhart, HM, et al. Pulmonary regurgitation after tetralogy of Fallot repair: clinical features, sequelae, and timing of pulmonary valve replacement. Congenit Heart Dis 2007; 2: 386–403.CrossRefGoogle ScholarPubMed
Geva, T.Repaired tetralogy of Fallot: the roles of cardiovascular magnetic resonance in evaluating pathophysiology and for pulmonary valve replacement decision support. J Cardiovasc Magn Reson 2011; 13: 1–24.CrossRefGoogle ScholarPubMed
Mueller, T, Djeplinger, B.The presage ST2 assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn 2013; 13: 13–30.CrossRefGoogle ScholarPubMed
de Boer, RA, Edelman, F, Cohen-Solal, A, et al. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Failure 2013; 15: 511–518.CrossRefGoogle ScholarPubMed
Santaguida, PL, Don-Wauchope, AC, Oremus, M, et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Failure Rev 2014; 19: 453–470.CrossRefGoogle ScholarPubMed
Eindhoven, JA, van den Bosch, AE, Boersma, E, et al. The usefulness of brain natriuretic peptide in simple congenital heart disease. Cardiol Young 2013; 23: 315–324.CrossRefGoogle ScholarPubMed
Koch, A, Singer, H.Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003; 89: 875–878CrossRefGoogle ScholarPubMed
Albers, S, Mir, TS, Haddad, M, et al. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med 2006; 44: 80–85CrossRefGoogle ScholarPubMed
Abman, SH, Hansmann, G, Archer, SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132: 2037–2099.CrossRefGoogle ScholarPubMed
McCarthy, C, Januzzi, JL JrSoluble ST2 in heart failure. Heart Fail Clin 2018; 14: 41–48.CrossRefGoogle ScholarPubMed
Lupu, S, Agoston-Coldea, L.Soluble ST2 in ventricular dysfunction. Advances in Clinical Chemistry. 2015; 69: 139–159.CrossRefGoogle ScholarPubMed
Paul, S, Harshaw-Ellis, K.Evolving use of biomarkers in the management of heart failure. Cardiol Rev 2019; 27: 153–159.CrossRefGoogle ScholarPubMed
Meeusen, JW, Johnson, JN, Gray, A, et al. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem 2015; 48: 1337–1340.CrossRefGoogle ScholarPubMed
Kotby, O, Youssef, OI, Elmaraghy, MO, et al. Galectin-3 in children with chronic heart failure with normal and reduced ejection fraction: relationship to disease severity. Pediatr Cardiol 2017; 38: 95–102.CrossRefGoogle ScholarPubMed
Mohammed, LA, Gafar, HS, Hussien, NR.Galectin-3 as early detector of heart failure in children with congenital acyanotic heart disease. Clin Med Diagn 2014; 4: 90–98.Google Scholar
Kunii, Y, Kamada, K, Ohtsuki, S, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003; 57: 191–197.Google ScholarPubMed
Eerola, A, Jokinen, E, Pihkala, J.Serum levels of natriuretic peptides in children with various types of loading conditions. Scand Cardiovasc J 2009; 43: 187–193.CrossRefGoogle ScholarPubMed
Jan, SL, Fu, YC, Hwang, B, et al. B-type natriuretic peptide in children with atrial or ventricular septal defect: a cardiac catheterization study. Biomarkers 2012; 17: 166–171.CrossRefGoogle ScholarPubMed
Pérez-Piaya, MR, Abarca, E, Soler, V, et al. Levels of N-terminal-pro-brain natriuretic peptide in congenital heart disease surgery and its value as a predictive biomarker. Interact Cardiovasc Thorac Surg 2011; 12: 461–466.CrossRefGoogle ScholarPubMed
Geva, T.Indications for pulmonary valve replacement in repaired tetralogy of Fallot: the quest continues. Circulation 2013; 128: 1855–1857.CrossRefGoogle ScholarPubMed